Abstracts tagged "giant cell arteritis"

Abstract Number: 0767 • ACR Convergence 2024
Comparing Large Vessel Uptake of 68Ga-HA-DOTATATE to 18F-FDG Using PET/CT Imaging in Patients with Active Giant Cell Arteritis
Alison Clifford¹, Jonathan Abele¹, Ryan Hung¹, Paolo Raggi¹, Frank Wuest¹, Jan Andersson¹, Elaine Yacyshyn², Eric Lenza¹, Glen Jickling¹ and Jan Willem Cohen Tervaert¹, ¹University of Alberta, Edmonton, Canada, ²University of Alberta, Edmonton, AB, Canada
Background/Purpose: 18F-fluoro-deoxyglucose (FDG) is the current standard among radiotracers for PET/CT imaging of large vessel vasculitis (LVV) in giant cell arteritis (GCA), but its performance…
Abstract Number: 1623 • ACR Convergence 2024
Sex Differences in Phenotypes and Imaging Examination in Giant Cell Arteritis: Data from the ARTESER Registry
Delia Fernández-Lozano¹, Marta Domínguez-Álvaro², Javier Narvaez-García³, Noemí Garrido-Puñal⁴, Eugenio De Miguel⁵, Paula Estrada-Alarcón⁶, Iñigo Hernández-Rodríguez⁷, Maite Silva-Diaz⁸, Joaquín M Belzunegui⁹, Clara Moriano¹⁰, Julio Sánchez-Martín¹¹, Itziar Calvo¹², Vicente Aldasoro¹³, lydia Abasolo Alcazar¹⁴, Javier Loricera¹⁵, Patricia Moya¹⁶, María García-Villanueva¹⁷, Fernando Sánchez-Alonso², Santos Castañeda¹⁸, José L. Hernández¹⁹ and Ricardo Blanco-Alonso²⁰, and ARTESER Project Collaborative Group, ¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Hospital Universitario Virgen del Rocío, Sevilla, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁷Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁸Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁹Hospital Universitario Donostia, San Sebastián, Spain, ¹⁰Hospital León, LEON, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Spain, ¹²Hospital Universitario de Basurto, Bilbao, Spain, ¹³Hospital Universitario de Navarra, Pamplona, Spain, ¹⁴IdISSC. HCSC, Madrid, Spain, ¹⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ¹⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁸Hospital Universitario de la Princesa, Madrid, Spain, ¹⁹University of Cantabria. IDIVAL, Santander, Spain, ²⁰Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is a predominantly female vasculitis. There are several studies that attempt to report the differences in the presentation of this…
Abstract Number: 1704 • ACR Convergence 2024
Cluster Analysis of Peripheral Blood Mononuclear Cell Subpopulations Using Deep Immunophenotyping, Multiplex Serum Cytokines and Small Lipid Mediators at the Very Early Stages of Steroid Treatment in Polymyalgia Rheumatica and Giant Cell Arteritis
Dimitrios Anastasios Palamidas¹, Maria Papadaki², Nikolaos Paschalidis³, Eleftherios Pavlos⁴, Loukas chatzis¹, Ourania Argyropoulou⁵, Panagiota Palla⁵, Ioanna-Evdokia Galani⁶, Andreas Goules⁷, Evangelos Andreakos⁴ and Athanasios Tzioufas⁸, ¹Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ²Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Attiki, Greece, ³Mass Cytometry-CyTOF Laboratory, Center for Clinical Research, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, Greece, Cholargos Athens, Greece, ⁴Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Athens, Greece, ⁵Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Athens, Greece, ⁶Laboratory of Immunobiology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens, Athens, 115 27, Greece., Cholargos Athens, Greece, ⁷GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁸LAIKO HOSPITAL, Athens, Greece
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are autoimmune/autoinflammatory disorders affecting patients over 50 years and are characterized by an acute inflammatory response.…
Abstract Number: 0077 • ACR Convergence 2023
Circulating CD4+CXCR5-PD-1hiICOS+ Cells Are Elevated in Patients with Newly Diagnosed Giant Cell Arteritis and Associate with the Clinical Outcome
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Irene Monjo², Mariela Uyaguari-Morocho¹, Irene Casado-Juárez³, Alejandro Balsa⁴ and Eugenio De Miguel⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²University Hospital La Paz, Madrid, Spain, ³Hospital La Paz - IdiPAZ, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel granulomatous vasculitis. It is characterized by the presence at the inflamed arterial walls, of activated PD-1+ CD4…
Abstract Number: 1133 • ACR Convergence 2023
Exploring the Clinical Characteristics and Correlation with Corticosteroid Dependence in Polymyalgia Rheumatica (PMR) Patients: Insights from an Academic Center
William Rigby¹, Todd Mackenzie², Emily Campbell¹, Joshua Skydel³, Bryan Savage¹, Monica Dimambro² and Vivekanand Tiwari¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Dartmouth College, Hanover, NH, ³Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is primarily based on long-term corticosteroids, which results in significant toxicities. Studies1,2 have shown that patients with PMR are exposed…
Abstract Number: 2388 • ACR Convergence 2023
Increased Risk of Severe Infections in Early Giant Cell Arteritis: A Population- based Study
Nazanin Naderi¹, Aladdin Mohammad², Karin Wadström³, Ulf Bergström³ and Carl Turesson³, ¹Lund University, Kristiandstad, Sweden, ²Lund University, Lund, Sweden, ³Lund University, Malmö, Sweden
Background/Purpose: Giant cell arteritis (GCA) is the most common type of vasculitis in adults aged 50 years or older. Although the substantial morbidity from infections…
Abstract Number: 2405 • ACR Convergence 2023
Role of Mitochondria in Activation of Platelets in Giant Cell Arteritis
Despoina Michailidou¹, Peter Grayson², Payton Hermanson¹, Jorge Armando Gonzalez-Chapa¹, David Cuthbertson³, Nader A. Khalidi⁴, Curry Koening⁵, Carol Langford⁶, Carol McAlear⁷, Larry Moreland⁸, Christian Pagnoux⁹, Philip Seo¹⁰, Antoine G Sreih¹¹, Kenneth Warrington¹², Paul Monach¹³, Peter Merkel⁷ and Christian Lood¹, ¹University of Washington, Seattle, WA, ²National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ³University of South Florida, Tampa, FL, ⁴McMaster University, Hamilton, ON, Canada, ⁵University of Texas Dell Medical School, Austin, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷University of Pennsylvania, Philadelphia, PA, ⁸University of Colorado, Denver, CO, ⁹Mount Sinai Hospital, Toronto, ON, Canada, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Bristol Myers Squibb, Princeton Pike, NJ, ¹²Mayo Clinic, Rochester, MN, ¹³VA Boston Healthcare System, Boston, MA
Background/Purpose: We recently found extracellular mitochondrial-derived N-formyl methionine in patients with giant cell arteritis (GCA. Extracellular mitochondria can be extruded by several mechanisms, including platelet…
Abstract Number: 2423 • ACR Convergence 2023
Concordance Between the 1990 ACR Classification Criteria and the New 2022 ACR/EULAR 2022 Criteria in Giant Cell Arteritis
Julio Sanchez Martin¹, Julia Medina Valle¹, Javier Loricera¹, Maria Fe Garcia Reija¹ and Ricardo Blanco², ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Classification criteria for vasculitis, including giant cell arteritis (GCA) are under constant revision. In 2022, the American College of Rheumatology (ACR)/European League Against Rheumatism…
Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 1538 • ACR Convergence 2023
Large Vessel Involvement in Antineutrophil Cytoplasmic Antibody- Associated Vasculitis: A Single Center Experience over Two Decades
Mahmut Kaymakci¹, Mohanad Elfishawi¹, Hannah Langenfeld², Andrew Hanson², Cynthia Crowson¹, Melanie Bois¹, Umar Ghaffar¹, Ulrich Specks¹, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) is currently categorized under the small vessel vasculitides and includes granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA),…
Abstract Number: 2389 • ACR Convergence 2023
Calprotectin (S100A8/S100A9) and Serumamyloid A Are Not Superior to C Reactive Protein and Erythrocyte Sedimentation Rate in Monitoring Disease Activity in Giant Cell Arteritis – Treated with or Without Tocilizumab
Matthias Froehlich¹, Marc Schmalzing², Hannah Labinsky³, Jan Portegys³, Ottar Gadeholt⁴, Patrick-Pascal Strunz¹, Eva C. Schwaneck⁵, Marcus Dittrich⁶, Tobias Mueller⁷ and Michael Gernert³, ¹Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Würzburg, Würzburg, Germany, ²University Hospital, Rheumatology/Clinical Immunology, Department of Internal Medicine II, Würzburg, Germany, ³Medical Department II, Rheumatology, University Hospital Würzburg, Würzburg, Germany, ⁴Rheumatologische Schwerpunktpraxis Würzburg, Würzburg, Germany, ⁵MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH, Hamburg, Germany, ⁶Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Germany ; Institute for Human Genetics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany, ⁷Department of Bioinformatics, Biocenter, Am Hubland, D-97074 University of Würzburg, Würzburg, Germany
Background/Purpose: Monitoring disease activity in giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) remains challenging as standard inflammation parameters, i.e., C-reactive protein (CRP) and erythrocyte…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 2424 • ACR Convergence 2023
Exploring the Limit of Image Resolution for Human Expert Classification of Vascular Ultrasound Images in Giant Cell Arteritis and Healthy Subjects: The GCA-US-AI Project
Valentin Sebastian Schäfer¹, Stavros Chrysidis², Christian Dejaco³, Sara Monti⁴, Matthew Koster⁵, Pantelis Karakostas¹, Wolfgang Schmidt⁶, Eugenio De Miguel⁷, Christina Duftner⁸, Alojzija Hocevar⁹, Annamaria Iagnocco¹⁰, Marcin Milchert¹¹, Chetan Mukhtyar¹², Cristina Ponte¹³, Lene Terslev¹⁴, Tanaz Kermani¹⁵, Uffe Møller Døhn¹⁶, Berit Dalsgaard Nielsen¹⁷, Aaron Juche¹⁸, Luca Seitz¹⁹, Minna Kohler²⁰, Kresten Keller²¹, Rositsa Karalilova²², Thomas Daikeler²³, Sarah Mackie²⁴, Karina Torralba²⁵, Kornelis van der Geest²⁶, Dennis Boumans²⁷, Philipp Bosch²⁸, Alessandro Tomelleri²⁹, Markus Aschwanden³⁰, Peter Brossart¹, Charlotte Behning³¹ and Claus Juergen Bauer¹, ¹Clinic of Internal Medicine III, Department of Oncology, Hematology, Rheumatology and Clinical Immunology, University Hospital of Bonn, Bonn, Germany, ²Department of Rheumatology, Southwest Jutland Hospital Esbjerg, Esbjerg, Denmark, ³Department of Rheumatology, Medical University Graz, Graz, Austria; Department of Rheumatology, Hospital of Bruneck (ASAA-SABES), Teaching Hospital of the Paracelsius Medical University, Brunico, Italy, ⁴Division of Rheumatology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Therapeutics, Università di Pavia, Pavia, Italy, ⁵Mayo Clinic, Rochester, MN, ⁶Rheumatology, Immanuel Krankenhaus Berlin, Medical Centre for Rheumatology Berlin-Buch, Berlin, Germany, ⁷Hospital Universitario La Paz, Madrid, Spain, ⁸Department of Internal Medicine, Clinical Division of Internal Medicine II, Medical University Innsbruck, Innsbruck, Austria, ⁹Department of Rheumatology, Universitiy Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁰University of Turin, Roma, Italy, ¹¹Department of Internal Medicine, Rheumatology, Diabetology, Geriatrics and Clinical Immunology, Pomeranian Medical University in Szczecin, Szczecin, Poland, ¹²Vasculitis service, Rheumatology department, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ¹³Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal, ¹⁴Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ¹⁵Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ¹⁶Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ¹⁷Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Medicine, The Regional Hospital in Horsens, Horsens, Denmark, ¹⁸Department of Rheumatology, Immanuel Hospital, Berlin, Germany, ¹⁹Rheumatology and Immunology, Inselspital University Hospital Bern, Bern, Switzerland, ²⁰Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²¹Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ²²Clinic of Rheumatology, Medical University Plovdiv, Plovdiv, Bulgaria, ²³Clinic for Rheumatology, University Hospital Basel, Basel, Switzerland, ²⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ²⁵Division of Rheumatology, Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA, ²⁶Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²⁷Rheumatology and Clinical Immunology, Hospital Group Twente, Almelo, Netherlands, ²⁸Medical University of Graz, Graz, Austria, ²⁹Unit of Immunology, Rheumatology, Allergy and Rare Diseases, San Raffaele Scientific Institute, Milano, Italy, ³⁰Department of Angiology, University Hospital Basel, Basel, Switzerland, ³¹Institute of Medical Biometry, Informatics and Epidemiology, University Hospital of Bonn, Bonn, Germany
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults, necessitating prompt diagnosis to prevent severe complications. However, access to expert…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 1565 • ACR Convergence 2023
Baseline Vascular Ultrasound of Polymyalgia Rheumatica Patients at Time of Diagnosis Predicts Clinical Outcomes at 3 Months
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴ and David Kane⁵, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: It has been reported that up to a quarter of patients with polymyalgia rheumatica (PMR) have subclinical giant cell arteritis (GCA). It is currently…

« Previous Page
1
…
7
8
9
10
11
…
36
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].